Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Slowing of brain atrophy and reductions in new multiple sclerosis lesions sustained at three years in patients treated with Genzyme's LemtradaTM
Endogenous opioids regulate the expression of inducible nitric oxide synthase by splenocytes.
Concurrent saturation transfer contrast in in vivo brain by a uniform magnetization transfer MRI.
Alemtuzumab (Lemtrada) - NICE says yes in final draft guidance
Multiple sclerosis: Does aggressive MS warrant aggressive treatment?
Bayer Receives FDA Approval for BETACONNECT - First and Only Electronic Autoinjector in Relapsing-Remitting Multiple Sclerosis (RRMS) Treatment
High levels of cerebrospinal fluid free kappa chains predict conversion to multiple sclerosis.
Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma.
A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis.
Metabolomic profiling in multiple sclerosis: insights into biomarkers and pathogenesis.
Natalizumab in the treatment of rheumatoid arthritis in subjects receiving methotrexate
Vitamin D: a natural inhibitor of multiple sclerosis.
Two discreet subsets of CD8 T cells modulate PLP(91-110) induced experimental autoimmune encephalomyelitis in HLA-DR3 transgenic mice.
Changed histone acetylation patterns in normal-appearing white matter and early multiple sclerosis lesions.
Direct angiotensin AT2-receptor stimulation attenuates T-cell and microglia activation and prevents demyelination in experimental autoimmune encephalomyelitis in mice.
B-07The Cognitive Health Questionnaire: Initial Psychometric Data in a Multisite Multiple Sclerosis Sample.
Embryonic stem cell lines derived from human blastocysts.
Identification of protein networks involved in the disease course of experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis.
Genome-wide association study of multiple sclerosis confirms a novel locus at 5p13.1.
Novartis receives European Commission approval for Gilenya®, the first oral multiple sclerosis treatment for use in the EU
From "Wheelchair Circuit" to "Wheelchair Assessment Instrument for People with Multiple Sclerosis": Reliability and Validity Analysis of a Test to Assess Driving Skills in Manual Wheelchair Users With Multiple Sclerosis.
An Adult Case of Anti-Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Multiphasic Acute Disseminated Encephalomyelitis at 33-year Intervals.
Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis.
PLEGRIDY™ (peginterferon beta-1a) approved in the European Union for the treatment of multiple sclerosis
Comment on the letter by Messori et al. (European Journal of Neurology 2013; 20: e131).

Pages